The biology and treatment of chronic myelogenous leukemia

Claudio G. Brunstein, Philip B. Mcglave

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to CML have been developed that increase the options available to newly diagnosed patients, and that can cure or prolong survival in this formerly incurable disease. Newly diagnosed patients presenting with extreme leukocytosis or thrombocytosis may benefit from immediate therapy with hydroxyurea (Hydrea) and pheresis. After stabilization, eligible patients may elect to undergo immediate transplant. The majority, however, should begin therapy with either interferon-alpha and cytarabine, or they should be entered into the STI-571 trials.

Original languageEnglish (US)
Pages (from-to)23-30
Number of pages8
Issue number1
StatePublished - Dec 1 2001


Dive into the research topics of 'The biology and treatment of chronic myelogenous leukemia'. Together they form a unique fingerprint.

Cite this